Identification

Name
Risedronate
Accession Number
DB00884  (APRD00410, DB02782)
Type
Small Molecule
Groups
Approved, Investigational
Description

Risedronate is a bisphosphonate used to strengthen bone, treat or prevent osteoporosis, and treat Paget's disease of bone.

Structure
Thumb
Synonyms
  • Acide risédroniqe
  • Acido risedronico
  • Acidum risedronicum
  • Ridron
  • Risedronate
  • Risedronic acid
  • Risedronsäure
External IDs
M05BA07 / NE-58095
Product Ingredients
IngredientUNIICASInChI Key
Risedronate sodiumOFG5EXG60L115436-72-1DRFDPXKCEWYIAW-UHFFFAOYNA-M
Risedronate sodium hemi-pentahydrateHU2YAQ274O329003-65-8HYFDYHPNTXOPPO-UHFFFAOYSA-L
Risedronate sodium monohydrateF67L43UT5C353228-19-0KLQNARDFMJRXSF-UHFFFAOYSA-M
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ActonelTablet5 mgOralAllergan Pharma Co.2000-07-25Not applicableCanada
ActonelTablet, film coated30 mg/1OralWarner Chilcott1998-03-27Not applicableUs
ActonelTablet, film coated150 mg/1OralWarner Chilcott2008-04-22Not applicableUs
ActonelTablet75 mgOralWarner Chilcott2007-08-132016-08-05Canada
ActonelTablet30 mgOralAllergan Pharma Co.1999-09-07Not applicableCanada
ActonelTablet, film coated150 mg/1OralPhysicians Total Care, Inc.2009-10-05Not applicableUs
ActonelTablet35 mgOralAllergan Pharma Co.2002-12-10Not applicableCanada
ActonelTablet, film coated5 mg/1OralWarner Chilcott2000-04-14Not applicableUs
ActonelTablet, film coated5 mg/1OralPhysicians Total Care, Inc.2002-03-15Not applicableUs
ActonelTablet150 mgOralAllergan Pharma Co.2008-12-01Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-risedronateTablet35 mgOralApotex Corporation2010-11-10Not applicableCanada
Apo-risedronateTablet150 mgOralApotex Corporation2012-05-17Not applicableCanada
Risedronate SodiumTablet, film coated75 mg/1OralMylan Pharmaceuticals2014-06-102016-01-07Us
Risedronate SodiumTablet, film coated35 mg/1OralMacleods Pharmaceuticals Limited2015-12-09Not applicableUs
Risedronate SodiumTablet, film coated35 mg/1OralSun Pharma Global FZE2015-11-30Not applicableUs
Risedronate SodiumTablet, film coated35 mg/1OralApotex Corporation2015-11-30Not applicableUs
Risedronate SodiumTablet, film coated30 mg/1OralTeva2015-06-01Not applicableUs00093 3100 56 nlmimage10 4043a01d
Risedronate SodiumTablet, film coated35 mg/1OralAurobindo Pharma2015-11-30Not applicableUs
Risedronate SodiumTablet, film coated150 mg/1OralMylan Pharmaceuticals2014-06-10Not applicableUs
Risedronate SodiumTablet, film coated30 mg/1OralMacleods Pharmaceuticals Limited2015-12-09Not applicableUs
International/Other Brands
Benet (Takeda )
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
ActonelRisedronate (150 mg)Tablet, film coatedOralAllergan2008-04-22Not applicableUs
ActonelRisedronate (35 mg)Tablet, film coatedOralAllergan2002-05-17Not applicableUs00430 0472 03 nlmimage10 08400400
ActonelRisedronate (30 mg)Tablet, film coatedOralAllergan1998-03-27Not applicableUs
ActonelRisedronate (5 mg)Tablet, film coatedOralAllergan2000-04-14Not applicableUs
Actonel Plus CalciumRisedronate sodium (35 mg) + Calcium (500 mg)TabletOralWarner Chilcott2006-05-182015-11-19Canada
Actonel Sachet KitRisedronate sodium (35 mg) + Calcium (1000 mg) + Cholecalciferol (880 unit)Granule, effervescent; Kit; TabletOralWarner ChilcottNot applicableNot applicableCanada
AtelviaRisedronate (35 mg)Tablet, delayed releaseOralWarner Chilcott2010-12-01Not applicableUs00430 0979 03 nlmimage10 8744c3d6
PMS-risedronate Plus CalciumRisedronate sodium (35 mg) + Calcium (500 mg)TabletOralPharmascience IncNot applicableNot applicableCanada
Risedronate SodiumRisedronate (75 mg/1)Tablet, film coatedOralActavis Pharma Company2014-06-27Not applicableUs
Risedronate SodiumRisedronate (30 mg/1)Tablet, film coatedOralActavis Pharma Company2014-06-27Not applicableUs
Categories
UNII
KM2Z91756Z
CAS number
105462-24-6
Weight
Average: 283.1123
Monoisotopic: 283.001074735
Chemical Formula
C7H11NO7P2
InChI Key
IIDJRNMFWXDHID-UHFFFAOYSA-N
InChI
InChI=1S/C7H11NO7P2/c9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6/h1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15)
IUPAC Name
[1-hydroxy-1-phosphono-2-(pyridin-3-yl)ethyl]phosphonic acid
SMILES
OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)(O)=O

Pharmacology

Indication

For the treatment of Paget's disease of the bone (osteitis deformans), postmenopausal and glucocorticoid-induced osteoporosis

Structured Indications
Pharmacodynamics

Risedronate is a pyridinyl bisphosphonate that inhibits osteoclast-mediated bone resorption and modulates bone metabolism and is indicated for the treatment and prevention of osteoporosis in postmenopausal women.

Mechanism of action

The action of risedronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Risedronate also targets farnesyl pyrophosphate (FPP) synthase. Nitrogen-containing bisphosphonates (such as pamidronate, alendronate, risedronate, ibandronate and zoledronate) appear to act as analogues of isoprenoid diphosphate lipids, thereby inhibiting FPP synthase, an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins. This activity inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass.

TargetActionsOrganism
AFarnesyl pyrophosphate synthase
inhibitor
Human
AHydroxylapatite
antagonist
Human
Absorption

Rapid absorption (~1 hr) after an oral dose, occurs throughout the upper gastrointestinal tract

Volume of distribution
  • 13.8 L/kg
Protein binding

~24%

Metabolism

No evidence found for metabolization of risedronate in humans or mammals

Route of elimination

Risedronate is excreted unchanged primarily via the kidney. Insignificant amounts (<0.1% of intravenous dose) of drug are excreted in the bile in rats.

Half life

1.5 hours

Clearance
  • 122 mL/min
  • 73 mL/min [osteopenic postmenopausal women]
Toxicity

Side effects include abdominal pain, anxiety, back pain, belching, bladder irritation, bone disorders and pain, bronchitis, bursitis, cataracts, chest pain, colitis, constipation, depression, diarrhea, difficulty breathing, dizziness, dry eyes, eye infection, flu-like symptoms, gas, headache, high blood pressure, infection, insomnia, itching, joint disorders and pain, leg cramps, muscle pain, muscle weakness, nausea, neck pain, nerve pain, pain, pneumonia, rash, ringing in ears, sinus problems, sore throat, stomach bleeding, stuffy or runny nose, swelling, tendon problems, tumor, ulcers, urinary tract infection, vertigo, vision problems, and weakness.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Risedronate Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Risedronate.Experimental
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Risedronate.Vet Approved
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Risedronate.Approved
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Risedronate.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Risedronate.Approved, Vet Approved
AclarubicinAclarubicin may increase the hypocalcemic activities of Risedronate.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Risedronate.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Risedronate.Approved, Withdrawn
AlfuzosinAlfuzosin may increase the hypotensive activities of Risedronate.Approved, Investigational
AlgeldrateThe serum concentration of Risedronate can be decreased when it is combined with Algeldrate.Experimental
AlmagateThe serum concentration of Risedronate can be decreased when it is combined with Almagate.Experimental
AlmasilateThe serum concentration of Risedronate can be decreased when it is combined with Almasilate.Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Risedronate.Experimental
AloglutamolThe serum concentration of Risedronate can be decreased when it is combined with Aloglutamol.Experimental
AluminiumThe serum concentration of Risedronate can be decreased when it is combined with Aluminium.Approved
Aluminium acetoacetateThe serum concentration of Risedronate can be decreased when it is combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe serum concentration of Risedronate can be decreased when it is combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe serum concentration of Risedronate can be decreased when it is combined with Aluminum hydroxide.Approved
AmikacinAmikacin may increase the hypocalcemic activities of Risedronate.Approved, Vet Approved
AmobarbitalThe metabolism of Risedronate can be increased when combined with Amobarbital.Approved, Illicit
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Risedronate.Approved
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Risedronate.Approved, Investigational
AmrubicinAmrubicin may increase the hypocalcemic activities of Risedronate.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Risedronate.Investigational
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Risedronate.Approved, Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Risedronate.Investigational
annamycinannamycin may increase the hypocalcemic activities of Risedronate.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Risedronate.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Risedronate.Investigational
ApramycinApramycin may increase the hypocalcemic activities of Risedronate.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Risedronate.Approved, Investigational
ArbekacinArbekacin may increase the hypocalcemic activities of Risedronate.Approved
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Risedronate.Approved
AsenapineThe serum concentration of Risedronate can be increased when it is combined with Asenapine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Risedronate is combined with Atorvastatin.Approved
AtosibanThe risk or severity of adverse effects can be increased when Risedronate is combined with Atosiban.Approved
Atracurium besylateRisedronate may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Risedronate.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Risedronate.Approved
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Risedronate.Experimental
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Risedronate.Approved, Investigational
BarbexacloneThe metabolism of Risedronate can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Risedronate can be increased when combined with Barbital.Illicit
BekanamycinBekanamycin may increase the hypocalcemic activities of Risedronate.Experimental
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Risedronate.Experimental
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Risedronate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Risedronate.Withdrawn
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Risedronate.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Risedronate.Experimental
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Risedronate.Approved
Bismuth SubcitrateThe serum concentration of Risedronate can be decreased when it is combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe serum concentration of Risedronate can be decreased when it is combined with Bismuth subnitrate.Experimental
Brefeldin AThe risk or severity of adverse effects can be increased when 1,6,7,8,9,11A,12,13,14,14A-DECAHYDRO-1,13-DIHYDROXY-6-METHYL-4H-CYCLOPENT[F]OXACYCLOTRIDECIN-4-ONE is combined with Risedronate.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Risedronate.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Risedronate.Investigational
BucindololBucindolol may increase the hypotensive activities of Risedronate.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Risedronate.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Risedronate.Experimental
BunazosinBunazosin may increase the hypotensive activities of Risedronate.Investigational
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Risedronate.Approved
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Risedronate.Approved
CalciumThe serum concentration of Risedronate can be decreased when it is combined with Calcium.Nutraceutical
Calcium AcetateThe serum concentration of Risedronate can be decreased when it is combined with Calcium Acetate.Approved
Calcium CarbonateThe serum concentration of Risedronate can be decreased when it is combined with Calcium Carbonate.Approved
Calcium CitrateThe serum concentration of Risedronate can be decreased when it is combined with Calcium Citrate.Approved
Calcium glubionateThe serum concentration of Risedronate can be decreased when it is combined with Calcium glubionate.Approved
Calcium GluceptateThe serum concentration of Risedronate can be decreased when it is combined with Calcium Gluceptate.Approved
Calcium gluconateThe serum concentration of Risedronate can be decreased when it is combined with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe serum concentration of Risedronate can be decreased when it is combined with Calcium lactate.Approved, Experimental, Vet Approved
Calcium lactate gluconateThe serum concentration of Risedronate can be decreased when it is combined with Calcium lactate gluconate.Experimental
Calcium laevulateThe serum concentration of Risedronate can be decreased when it is combined with Calcium laevulate.Experimental
Calcium pangamateThe serum concentration of Risedronate can be decreased when it is combined with Calcium pangamate.Experimental
Calcium PhosphateThe serum concentration of Risedronate can be decreased when it is combined with Calcium Phosphate.Approved
Calcium silicateThe serum concentration of Risedronate can be decreased when it is combined with Calcium silicate.Experimental
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Risedronate.Withdrawn
Capric acidThe risk or severity of adverse effects can be increased when Capric acid is combined with Risedronate.Experimental
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Risedronate.Experimental
CarbomycinThe metabolism of Risedronate can be decreased when combined with Carbomycin.Vet Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Risedronate.Approved, Vet Approved, Withdrawn
CarvedilolCarvedilol may increase the hypotensive activities of Risedronate.Approved, Investigational
CaseinThe serum concentration of Risedronate can be decreased when it is combined with Casein.Approved
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Risedronate.Approved
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Risedronate.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Risedronate.Approved, Investigational
CerivastatinThe risk or severity of adverse effects can be increased when Risedronate is combined with Cerivastatin.Withdrawn
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Risedronate.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Risedronate.Approved, Vet Approved
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Risedronate.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Risedronate.Approved
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Risedronate.Approved, Investigational
ClarithromycinThe metabolism of Risedronate can be decreased when combined with Clarithromycin.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Risedronate.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Risedronate.Approved, Nutraceutical
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Risedronate.Approved, Vet Approved
CordycepinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Risedronate.Investigational
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Risedronate.Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Risedronate.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Risedronate.Investigational
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Risedronate.Investigational
DaunorubicinDaunorubicin may increase the hypocalcemic activities of Risedronate.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Risedronate is combined with Deferasirox.Approved, Investigational
DexlansoprazoleThe therapeutic efficacy of Risedronate can be decreased when used in combination with Dexlansoprazole.Approved
DexrabeprazoleThe therapeutic efficacy of Risedronate can be decreased when used in combination with Dexrabeprazole.Experimental
DibekacinDibekacin may increase the hypocalcemic activities of Risedronate.Experimental
DichloropheneThe risk or severity of adverse effects can be increased when Dichlorophene is combined with Risedronate.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Risedronate.Approved, Vet Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Risedronate.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Risedronate.Approved
DihydrostreptomycinDihydrostreptomycin may increase the hypocalcemic activities of Risedronate.Vet Approved
DoxazosinDoxazosin may increase the hypotensive activities of Risedronate.Approved
DoxepinThe serum concentration of Risedronate can be increased when it is combined with Doxepin.Approved
DoxorubicinDoxorubicin may increase the hypocalcemic activities of Risedronate.Approved, Investigational
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Risedronate.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Risedronate.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Risedronate.Investigational
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Risedronate.Approved
EfavirenzThe serum concentration of Risedronate can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Risedronate.Approved
EpinastineThe serum concentration of Risedronate can be increased when it is combined with Epinastine.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Risedronate.Approved
EpirubicinEpirubicin may increase the hypocalcemic activities of Risedronate.Approved
ErythromycinThe metabolism of Risedronate can be decreased when combined with Erythromycin.Approved, Vet Approved
EsomeprazoleThe therapeutic efficacy of Risedronate can be decreased when used in combination with Esomeprazole.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Risedronate.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Risedronate.Experimental
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Risedronate.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Risedronate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Risedronate.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Risedronate.Approved
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Risedronate.Investigational
FamotidineThe serum concentration of Risedronate can be increased when it is combined with Famotidine.Approved
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Risedronate.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Risedronate.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Risedronate.Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Risedronate.Experimental
FenticonazoleThe risk or severity of adverse effects can be increased when Fenticonazole is combined with Risedronate.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Risedronate.Experimental
Ferric CitrateThe serum concentration of Risedronate can be decreased when it is combined with Ferric Citrate.Approved
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Risedronate.Experimental
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Risedronate.Approved, Withdrawn
FluconazoleThe serum concentration of Risedronate can be increased when it is combined with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Risedronate.Approved
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Risedronate.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Risedronate.Experimental
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Risedronate.Approved, Investigational
FlutrimazoleThe risk or severity of adverse effects can be increased when Flutrimazole is combined with Risedronate.Experimental
FluvastatinThe risk or severity of adverse effects can be increased when Risedronate is combined with Fluvastatin.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Risedronate.Approved
FramycetinFramycetin may increase the hypocalcemic activities of Risedronate.Approved
GeneticinGeneticin may increase the hypocalcemic activities of Risedronate.Experimental
GentamicinGentamicin may increase the hypocalcemic activities of Risedronate.Approved, Vet Approved
GENTAMICIN C1AGENTAMICIN C1A may increase the hypocalcemic activities of Risedronate.Experimental
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Risedronate.Experimental
GPX-150GPX-150 may increase the hypocalcemic activities of Risedronate.Investigational
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Risedronate.Approved, Vet Approved
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Risedronate.Experimental
HachimycinThe risk or severity of adverse effects can be increased when Hachimycin is combined with Risedronate.Experimental
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Risedronate.Approved, Withdrawn
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Risedronate.Approved
HexobarbitalThe metabolism of Risedronate can be increased when combined with Hexobarbital.Approved
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Risedronate.Investigational
HydrotalciteThe serum concentration of Risedronate can be decreased when it is combined with Hydrotalcite.Experimental
Hygromycin BHygromycin B may increase the hypocalcemic activities of Risedronate.Vet Approved
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Risedronate.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Risedronate.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Risedronate.Approved
IdarubicinIdarubicin may increase the hypocalcemic activities of Risedronate.Approved
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Risedronate.Experimental
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Risedronate.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Risedronate.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Risedronate.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Risedronate.Withdrawn
INNO-206INNO-206 may increase the hypocalcemic activities of Risedronate.Investigational
Iron saccharateThe serum concentration of Risedronate can be decreased when it is combined with Iron saccharate.Approved
IsepamicinIsepamicin may increase the hypocalcemic activities of Risedronate.Experimental
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Risedronate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Risedronate.Withdrawn
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Risedronate.Approved, Investigational
JosamycinThe metabolism of Risedronate can be decreased when combined with Josamycin.Approved
KanamycinKanamycin may increase the hypocalcemic activities of Risedronate.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Risedronate.Experimental
KetoconazoleThe risk or severity of adverse effects can be increased when Ketoconazole is combined with Risedronate.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Risedronate.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Risedronate.Approved
KitasamycinThe metabolism of Risedronate can be decreased when combined with Kitasamycin.Experimental
LabetalolLabetalol may increase the hypotensive activities of Risedronate.Approved
LansoprazoleThe therapeutic efficacy of Risedronate can be decreased when used in combination with Lansoprazole.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Risedronate.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Risedronate.Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Risedronate.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Risedronate.Approved
LovastatinThe risk or severity of adverse effects can be increased when Risedronate is combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Risedronate.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Risedronate.Approved, Investigational
Magnesium HydroxideThe serum concentration of Risedronate can be decreased when it is combined with Magnesium Hydroxide.Approved
Magnesium oxideThe serum concentration of Risedronate can be decreased when it is combined with Magnesium oxide.Approved
Magnesium peroxideThe serum concentration of Risedronate can be decreased when it is combined with Magnesium peroxide.Experimental
Magnesium salicylateThe serum concentration of Risedronate can be decreased when it is combined with Magnesium salicylate.Approved
Magnesium silicateThe serum concentration of Risedronate can be decreased when it is combined with Magnesium silicate.Experimental
Magnesium SulfateThe serum concentration of Risedronate can be decreased when it is combined with Magnesium Sulfate.Approved, Vet Approved
Magnesium TrisilicateThe serum concentration of Risedronate can be decreased when it is combined with Magnesium Trisilicate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Risedronate.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Risedronate.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Risedronate.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Risedronate.Approved, Vet Approved
MepartricinThe risk or severity of adverse effects can be increased when Mepartricin is combined with Risedronate.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Risedronate.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Risedronate.Withdrawn
MethanthelineThe serum concentration of Risedronate can be increased when it is combined with Methantheline.Approved
MethohexitalThe metabolism of Risedronate can be increased when combined with Methohexital.Approved
MethylphenobarbitalThe metabolism of Risedronate can be increased when combined with Methylphenobarbital.Approved
MetiamideThe serum concentration of Risedronate can be increased when it is combined with Metiamide.Experimental
MetrizamideMetrizamide may increase the hypocalcemic activities of Risedronate.Approved
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Risedronate.Experimental
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Risedronate.Approved, Investigational
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Risedronate.Approved, Investigational, Vet Approved
MicronomicinMicronomicin may increase the hypocalcemic activities of Risedronate.Experimental
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Risedronate.Approved
MivacuriumRisedronate may increase the neuromuscular blocking activities of Mivacurium.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Risedronate.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Risedronate.Experimental
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Risedronate.Vet Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Risedronate.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Risedronate.Approved
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Risedronate.Experimental
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Risedronate.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Risedronate.Approved, Investigational
NafcillinThe metabolism of Risedronate can be increased when combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Risedronate.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Risedronate.Approved, Vet Approved
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Risedronate.Approved
NeamineNeamine may increase the hypocalcemic activities of Risedronate.Experimental
NeomycinNeomycin may increase the hypocalcemic activities of Risedronate.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Risedronate.Approved
NetilmicinNetilmicin may increase the hypocalcemic activities of Risedronate.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Risedronate.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Risedronate.Approved
NifuratelThe risk or severity of adverse effects can be increased when Nifuratel is combined with Risedronate.Experimental
Nikkomycin ZThe risk or severity of adverse effects can be increased when Nikkomycin Z is combined with Risedronate.Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Risedronate.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Risedronate.Investigational
NitroprussideRisedronate may increase the hypotensive activities of Nitroprusside.Approved
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Risedronate.Approved
NizatidineThe serum concentration of Risedronate can be increased when it is combined with Nizatidine.Approved
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Risedronate.Approved, Vet Approved
OlanzapineThe serum concentration of Risedronate can be increased when it is combined with Olanzapine.Approved, Investigational
OleandomycinThe metabolism of Risedronate can be decreased when combined with Oleandomycin.Vet Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Risedronate.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Risedronate.Approved
OmeprazoleThe therapeutic efficacy of Risedronate can be decreased when used in combination with Omeprazole.Approved, Investigational, Vet Approved
OmoconazoleThe risk or severity of adverse effects can be increased when Omoconazole is combined with Risedronate.Experimental
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Risedronate.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Risedronate.Approved
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Risedronate.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Risedronate.Withdrawn
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Risedronate.Investigational
PantoprazoleThe therapeutic efficacy of Risedronate can be decreased when used in combination with Pantoprazole.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Risedronate.Approved
ParomomycinParomomycin may increase the hypocalcemic activities of Risedronate.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Risedronate.Investigational
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Risedronate.Approved
PentobarbitalThe metabolism of Risedronate can be increased when combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe metabolism of Risedronate can be increased when combined with Phenobarbital.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Risedronate.Approved, Vet Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Risedronate.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Risedronate.Approved, Investigational
PirarubicinPirarubicin may increase the hypocalcemic activities of Risedronate.Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Risedronate.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Risedronate.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Risedronate.Experimental
PitavastatinThe risk or severity of adverse effects can be increased when Risedronate is combined with Pitavastatin.Approved
PlazomicinPlazomicin may increase the hypocalcemic activities of Risedronate.Investigational
PlicamycinPlicamycin may increase the hypocalcemic activities of Risedronate.Approved, Withdrawn
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Risedronate.Approved, Investigational, Vet Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Risedronate.Experimental
PravastatinThe risk or severity of adverse effects can be increased when Risedronate is combined with Pravastatin.Approved
PrazosinPrazosin may increase the hypotensive activities of Risedronate.Approved
PrimidoneThe metabolism of Risedronate can be increased when combined with Primidone.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Risedronate.Experimental
PromethazineThe serum concentration of Risedronate can be increased when it is combined with Promethazine.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Risedronate.Approved
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Risedronate.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Risedronate.Experimental
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Risedronate.Investigational
PuromycinPuromycin may increase the hypocalcemic activities of Risedronate.Experimental
PyrrolnitrinThe risk or severity of adverse effects can be increased when Pyrrolnitrin is combined with Risedronate.Experimental
RabeprazoleThe therapeutic efficacy of Risedronate can be decreased when used in combination with Rabeprazole.Approved, Investigational
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Risedronate.Experimental
RanitidineThe serum concentration of Risedronate can be increased when it is combined with Ranitidine.Approved
RapacuroniumRisedronate may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Risedronate.Experimental, Investigational
RibostamycinRibostamycin may increase the hypocalcemic activities of Risedronate.Approved
RifabutinThe serum concentration of Risedronate can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Risedronate can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Risedronate can be decreased when it is combined with Rifapentine.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Risedronate.Investigational, Withdrawn
RosuvastatinThe risk or severity of adverse effects can be increased when Risedronate is combined with Rosuvastatin.Approved
Roxatidine acetateThe serum concentration of Risedronate can be increased when it is combined with Roxatidine acetate.Approved
SabarubicinSabarubicin may increase the hypocalcemic activities of Risedronate.Investigational
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Risedronate.Approved
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Risedronate.Experimental
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Risedronate.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Risedronate.Approved
SecobarbitalThe metabolism of Risedronate can be increased when combined with Secobarbital.Approved, Vet Approved
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Risedronate.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Risedronate.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Risedronate.Investigational
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Risedronate.Approved
SilodosinSilodosin may increase the hypotensive activities of Risedronate.Approved
SimvastatinThe risk or severity of adverse effects can be increased when Risedronate is combined with Simvastatin.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Risedronate.Experimental
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Risedronate.Approved, Investigational
SisomicinSisomicin may increase the hypocalcemic activities of Risedronate.Investigational
SolithromycinThe metabolism of Risedronate can be decreased when combined with Solithromycin.Investigational
SP1049CSP1049C may increase the hypocalcemic activities of Risedronate.Investigational
SpectinomycinSpectinomycin may increase the hypocalcemic activities of Risedronate.Approved, Vet Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Risedronate.Investigational
StreptomycinStreptomycin may increase the hypocalcemic activities of Risedronate.Approved, Vet Approved
StreptozocinStreptozocin may increase the hypocalcemic activities of Risedronate.Approved
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Risedronate.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Risedronate.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Risedronate.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Risedronate.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Risedronate.Experimental
TamsulosinTamsulosin may increase the hypotensive activities of Risedronate.Approved, Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Risedronate.Investigational
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Risedronate.Approved
TelithromycinThe metabolism of Risedronate can be decreased when combined with Telithromycin.Approved
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Risedronate.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Risedronate.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Risedronate.Vet Approved
TerazosinTerazosin may increase the hypotensive activities of Risedronate.Approved
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Risedronate.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Risedronate.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Risedronate.Approved
ThiamylalThe metabolism of Risedronate can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Risedronate can be increased when combined with Thiopental.Approved, Vet Approved
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Risedronate.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Risedronate.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Risedronate.Investigational
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Risedronate.Approved
TobramycinTobramycin may increase the hypocalcemic activities of Risedronate.Approved, Investigational
TolciclateThe risk or severity of adverse effects can be increased when Tolciclate is combined with Risedronate.Experimental
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Risedronate.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Risedronate.Approved
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Risedronate.Approved, Vet Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Risedronate.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Risedronate.Experimental
TrimazosinTrimazosin may increase the hypotensive activities of Risedronate.Experimental
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Risedronate.Approved, Investigational
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Risedronate.Investigational
TylosinThe metabolism of Risedronate can be decreased when combined with Tylosin.Vet Approved
UbidecarenoneThe risk or severity of adverse effects can be increased when Risedronate is combined with Ubidecarenone.Experimental
UrapidilUrapidil may increase the hypotensive activities of Risedronate.Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Risedronate.Investigational, Withdrawn
ValrubicinValrubicin may increase the hypocalcemic activities of Risedronate.Approved
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Risedronate.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Risedronate.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Risedronate.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Risedronate.Withdrawn
Zoptarelin doxorubicinZoptarelin doxorubicin may increase the hypocalcemic activities of Risedronate.Investigational
ZorubicinZorubicin may increase the hypocalcemic activities of Risedronate.Experimental
Food Interactions
Not Available

References

Synthesis Reference

Srinivasa Rao V.N Divvela, Lenin Racha, Sivakumaran Meenakshisunderam, Ramesh Dandala, "Process for the preparation of risedronate sodium hemi-pentahydrate." U.S. Patent US20070173484, issued July 26, 2007.

US20070173484
General References
Not Available
External Links
Human Metabolome Database
HMDB15022
KEGG Compound
C08233
PubChem Compound
5245
PubChem Substance
46507526
ChemSpider
5055
BindingDB
12576
ChEBI
8869
ChEMBL
CHEMBL923
Therapeutic Targets Database
DAP000658
PharmGKB
PA451255
HET
RIS
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Risedronate
ATC Codes
M05BB02 — Risedronic acid and calcium, sequentialM05BA07 — Risedronic acidM05BB04 — Risedronic acid, calcium and colecalciferol, sequentialM05BB07 — Risedronic acid and colecalciferol
AHFS Codes
  • 92:00.00
PDB Entries
FDA label
Download (1.52 MB)
MSDS
Download (57 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableBioavailability1
1CompletedNot AvailableNon-lactating / One to five years postmenopausal / Surgically Sterile1
1CompletedNot AvailableBone destruction / Osteopenia1
1CompletedNot AvailableBone destruction1
2CompletedTreatmentPostmenopausal Osteoporosis (PMO)1
2CompletedTreatmentPostmenopausal Women1
2CompletedTreatmentOne to five years postmenopausal1
2RecruitingBasic ScienceOsteogenesis Imperfecta1
2Unknown StatusTreatmentOsteoporosis, Post-Menopausal1
2, 3Active Not RecruitingTreatmentInvolutional Osteoporosis1
2, 3CompletedTreatmentAnorexia Nervosa (AN)1
2, 3CompletedTreatmentInvolutional Osteoporosis1
2, 3Unknown StatusTreatmentFibrous Dysplasia of Bone1
3CompletedDiagnosticBone destruction / Cancer, Breast1
3CompletedPreventionAcute Spinal Cord Injury1
3CompletedPreventionOsteopenia1
3CompletedPreventionPostmenopausal Osteoporosis (PMO)1
3CompletedPreventionProstate Cancer1
3CompletedSupportive CareBone destruction / Cancer, Breast1
3CompletedSupportive CareBone destruction / Prostate Cancer1
3CompletedTreatmentBack Pain / Postmenopausal Osteoporosis (PMO) / Vertebral Fractures1
3CompletedTreatmentCancer, Breast / Menopause / Osteopenia1
3CompletedTreatmentLeukemias / Malignant Lymphomas1
3CompletedTreatmentOsteogenesis Imperfecta1
3CompletedTreatmentOther Osteoporosis1
3CompletedTreatmentPaget's Disease of Bone2
3CompletedTreatmentPostmenopausal Osteoporosis (PMO)5
3CompletedTreatmentPostmenopausal Women Osteoporosis1
3CompletedTreatmentPostmenopausal Women With Osteoporosis1
3CompletedTreatmentBone destruction7
3RecruitingTreatmentOsteopenia1
3RecruitingTreatmentProsthesis Loosening1
3TerminatedPreventionMetastatic Hormone Refractory Prostate Cancer1
3WithdrawnSupportive CareBone destruction / Cancer, Breast1
4CompletedNot AvailableCrohn's Disease (CD) / Low Bone Mineral Density1
4CompletedNot AvailableBone destruction1
4CompletedPreventionBone destruction / Bone Loss / Cancer, Breast1
4CompletedPreventionBone destruction / Bone Loss / Epilepsies / Fracture Bone1
4CompletedPreventionBone destruction / Cystic Fibrosis (CF) / Muscular Dystrophy1
4CompletedPreventionPostmenopausal Osteoporosis (PMO)1
4CompletedTreatmentBone Loss1
4CompletedTreatmentCancer, Breast1
4CompletedTreatmentColles' Fracture1
4CompletedTreatmentPost Menopausal Osteoporosis1
4CompletedTreatmentPostmenopausal Osteoporosis (PMO)6
4CompletedTreatmentProstate Cancer1
4CompletedTreatmentBone destruction4
4RecruitingTreatmentFracture of Neck of Femur / Osteoporotic Fractures1
4TerminatedPreventionPostmenopausal Osteoporosis (PMO)1
4TerminatedTreatmentBone destruction2
4Unknown StatusPreventionPeriodontal Diseases1
4Unknown StatusTreatmentBone destruction1
Not AvailableActive Not RecruitingNot AvailableBone destruction1
Not AvailableCompletedNot AvailableAdenocarcinomas / Esophageal Cancers / Squamous Cell Carcinoma (SCC)1
Not AvailableCompletedNot AvailableOsseous Paget's Disease1
Not AvailableCompletedNot AvailableBone destruction1
Not AvailableCompletedPreventionHip Fractures1
Not AvailableCompletedPreventionBone destruction1
Not AvailableEnrolling by InvitationNot AvailableAtypical Femoral Fractures / Bisphosphonate Therapy / Bone destruction1
Not AvailableRecruitingTreatmentAnorexia Nervosa (AN) / Bone destruction / Osteopenia1
Not AvailableTerminatedTreatmentOsteopenia1

Pharmacoeconomics

Manufacturers
  • Warner chilcott co llc
  • Teva pharmaceuticals usa
  • Procter & Gamble
Packagers
Dosage forms
FormRouteStrength
TabletOral75 mg
Tablet, film coatedOral150 mg/1
Tablet, film coatedOral30 mg/1
Tablet, film coatedOral35 mg/1
Tablet, film coatedOral5 mg/1
Tablet, delayed releaseOral35 mg
Granule, effervescent; kit; tabletOral
TabletOral150 mg
TabletOral
Tablet, delayed releaseOral
Tablet, delayed releaseOral35 mg/1
Tablet, film coatedOral
Tablet, film coatedOral75 mg/1
TabletOral30 mg
TabletOral35 mg
TabletOral5 mg
Prices
Unit descriptionCostUnit
Actonel 150 mg tablet125.1USD tablet
Actonel 4 35 mg tablet Disp Pack119.43USD disp
Actonel 75 mg tablet54.83USD tablet
Actonel 30 mg tablet29.32USD tablet
Actonel 35 mg tablet28.75USD tablet
Actonel 5 mg tablet4.13USD tablet
Actonel with calcium tablet3.92USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6096342No1994-11-222011-11-22Us
CA2294595No2001-08-212018-07-17Canada
CA2399976No2007-03-272021-02-01Canada
US7192938Yes2003-11-062023-11-06Us
US7718634Yes2003-11-062023-11-06Us
US6165513Yes1998-12-102018-12-10Us
US5994329Yes1999-01-172019-01-17Us
US6015801Yes1999-01-172019-01-17Us
US6432932Yes1999-01-172019-01-17Us
US6465443Yes1999-02-142019-02-14Us
US7645459No2008-01-092028-01-09Us
US7645460No2008-01-092028-01-09Us
US8246989No2006-01-162026-01-16Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP-3.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility10.4 mg/mLALOGPS
logP-0.75ALOGPS
logP-3.3ChemAxon
logS-1.4ALOGPS
pKa (Strongest Acidic)0.68ChemAxon
pKa (Strongest Basic)4.91ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area148.18 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity57.12 m3·mol-1ChemAxon
Polarizability21.91 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9357
Blood Brain Barrier+0.9172
Caco-2 permeable-0.6795
P-glycoprotein substrateNon-substrate0.6846
P-glycoprotein inhibitor INon-inhibitor0.9582
P-glycoprotein inhibitor IINon-inhibitor1.0
Renal organic cation transporterNon-inhibitor0.9542
CYP450 2C9 substrateNon-substrate0.8452
CYP450 2D6 substrateNon-substrate0.8162
CYP450 3A4 substrateNon-substrate0.7208
CYP450 1A2 substrateNon-inhibitor0.8778
CYP450 2C9 inhibitorNon-inhibitor0.8792
CYP450 2D6 inhibitorNon-inhibitor0.9062
CYP450 2C19 inhibitorNon-inhibitor0.8777
CYP450 3A4 inhibitorNon-inhibitor0.9068
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.989
Ames testNon AMES toxic0.7663
CarcinogenicityNon-carcinogens0.8386
BiodegradationNot ready biodegradable0.5058
Rat acute toxicity2.1053 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9095
hERG inhibition (predictor II)Non-inhibitor0.9303
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as bisphosphonates. These are organic compounds containing two phosphonate groups linked together through a carbon atoms.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Organic phosphonic acids and derivatives
Sub Class
Bisphosphonates
Direct Parent
Bisphosphonates
Alternative Parents
Pyridines and derivatives / Organic phosphonic acids / Heteroaromatic compounds / Azacyclic compounds / Organopnictogen compounds / Organophosphorus compounds / Organooxygen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
Bisphosphonate / Pyridine / Heteroaromatic compound / Organophosphonic acid / Azacycle / Organoheterocyclic compound / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound / Organic oxide
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
pyridines (CHEBI:8869)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Poly(a) rna binding
Specific Function
Key enzyme in isoprenoid biosynthesis which catalyzes the formation of farnesyl diphosphate (FPP), a precursor for several classes of essential metabolites including sterols, dolichols, carotenoids...
Gene Name
FDPS
Uniprot ID
P14324
Uniprot Name
Farnesyl pyrophosphate synthase
Molecular Weight
48275.03 Da
References
  1. Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G: Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys. 2000 Jan 1;373(1):231-41. [PubMed:10620343]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  3. Coxon FP, Ebetino FH, Mules EH, Seabra MC, McKenna CE, Rogers MJ: Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo. Bone. 2005 Sep;37(3):349-58. [PubMed:16006204]
  4. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001 Feb;296(2):235-42. [PubMed:11160603]
  5. Ortiz-Gomez A, Jimenez C, Estevez AM, Carrero-Lerida J, Ruiz-Perez LM, Gonzalez-Pacanowska D: Farnesyl diphosphate synthase is a cytosolic enzyme in Leishmania major promastigotes and its overexpression confers resistance to risedronate. Eukaryot Cell. 2006 Jul;5(7):1057-64. [PubMed:16835450]
  6. Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, Kavanagh KL, Triffitt JT, Lundy MW, Phipps RJ, Barnett BL, Coxon FP, Rogers MJ, Watts NB, Ebetino FH: Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci. 2007 Nov;1117:209-57. [PubMed:18056045]
Kind
Small molecule
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
References
  1. Jahnke W, Henry C: An in vitro assay to measure targeted drug delivery to bone mineral. ChemMedChem. 2010 May 3;5(5):770-6. doi: 10.1002/cmdc.201000016. [PubMed:20209564]
  2. Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH: Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006 May;38(5):617-27. Epub 2005 Jul 20. [PubMed:16046206]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Valenti MT, Giannini S, Donatelli L, Zanatta M, Bertoldo F, Sella S, Vilei MT, Ossi E, Realdi G, Lo Cascio V, Dalle Carbonare L: The effect of risedronate on osteogenic lineage is mediated by cyclooxygenase-2 gene upregulation. Arthritis Res Ther. 2010;12(4):R163. doi: 10.1186/ar3122. Epub 2010 Aug 25. [PubMed:20738860]

Drug created on June 13, 2005 07:24 / Updated on October 19, 2017 15:00